consum remain factor
number factor addit revenu
growth continu await better visibl driver matter
consum growth believ manag revenu guidanc
screen achiev context overal portfolio first novaseq
instrument placement impli increment sale y/i
midpoint overal top line second management note array grow
around compani averag estim ad top line growth third
growth servic appear sustain given tailwind consum test
estim would add least increment top line growth fourth iseq
launch drive new lower-throughput opportun compani
addit top line growth manufactur ramp fifth believ invest
helix grail could add top line growth final fx could add
top line growth current rate minimum factor provid visibl
almost revenu growth
implic either guidanc conserv
consum growth continu moder instal base
begin undergo signific transit persist sever year
specif compani note expect high-throughput custom hiseq
hiseq begin transit work novaseq price point per gb
meaning lower transit give us paus context deceler
annual consum trend everi year prior
view consum growth import driver
thesi need better convict growth order justifi valuat
rais price target improv visibl reiter equal
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
equal weight leader next
gener sequenc market
project growth
posit fundament
impress compani abil transform
genom market believ sentiment well
reflect share
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ebitda billion
given pace innov cycl next
gener sequenc believ still
earli declar instrument choic
clinic use downsid case reflect
downsid ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
number factor addit revenu growth
continu await better visibl driver matter
consum growth believ manag revenu guidanc
screen achiev context overal portfolio first novaseq instrument
placement impli increment sale y/i midpoint
overal top line second management note array grow around compani
averag estim ad top line growth third growth servic appear
sustain given tailwind consum test estim would add least
increment top line growth fourth iseq launch drive new lower-
throughput opportun compani addit top line growth
manufactur ramp fifth believ invest helix grail could add
top line growth final fx could add top line growth current rate
minimum factor provid visibl almost revenu growth
implic either guidanc conserv
consum growth continu moder instal base begin
undergo signific transit persist sever year specif
compani note expect high-throughput custom hiseq hiseq begin
transit work novaseq price point per gb meaning lower
transit give us paus context deceler annual consum trend
everi year prior view
consum growth import driver thesi need better
convict growth order justifi valuat reiter equal weight rate
rais price target reflect greater visibl
revenu growth price target repres ebitda billion
prior price target repres prior ebitda forecast billion
reiter guidanc releas januari
remind revenu ep project estim time
compani expect revenu growth y/i driver growth
expect includ novaseq util demand clinic translat custom
well growth consum market expect place novaseq
ep expect rang includ
anticip benefit due tax reform ep dilut helix cfo ad
describ benefit lower statutori tax rate partial off-set higher
intern tax midpoint ep guidanc repres growth y/i
embed guidanc assumpt gross margin expand slightli
expect sequenti deceler revenu driven normal
season difficult comparison million stock order
expect repeat
novaseq placement high
expect flat sequenti total novaseq placement
exclud million order novaseq consum grew
sequenti though low base ceo desouza note introduct
flow cell import drive placement also continu
confid novaseq expand whole-genom sequenc market
custom quarter either new upgrad compani
desktop sequenc platform compani still believ earli stage
replac cycl approxim high throughput custom
adopt novaseq regard futur desouza note
compani expect place novaseq desouza also touch
number on-going whole genom sequenc initi exampl regeneron
work sequenc genom english biobank
model forecast novaseq placement
averag consum pull-through follow expect drop-off
placement includ assum approxim
placement replac come hiseq custom possibl compani
could see cannib hiseq custom well given rel advantag
novaseq forecast million novaseq revenu year
launch compar million nextseq revenu million
hiseq revenu year launch
market clearli excit prospect novaseq said continu
debat around capac constraint upper end sequenc market
face headwind high-throughput sequenc market
impact sale hiseq line sequenc manifest lower instrument
sale well lower consum pull-through hiseq
versu prior rang introduct novaseq offer cost
qualiti ease-of-us turnaround advantag custom compani believ
drive price point sequenc expand market said
launch inher differ prior launch given rel matur
compani custom note consum growth moder
follow growth growth year prior
new product launch import drive top line growth increas
sequenc demand analyz success last major new product cycl
hiseq nextseq introduct found strong
product launch begin carri compani
busi line grown modestli specif
competitor industri confer introduc hiseq nextseq
follow launch estim product contribut million
revenu place hiseq instrument million
nextseq system lead overal revenu growth momentum remain
strong leverag instal base higher consum growth
believ factor contribut signific interest launch
hiseq view game-chang whole-genom sequenc push price
point sequenc nextseq fill gap portfolio
first major product launch two year hiseq
hiseq nextseq meaning contributor overal revenu growth
sinc launch novaseq help improv visibl
specif estim hiseq nextseq product contribut
revenu growth balanc illumina
portfolio seen modest revenu growth
look portfolio similarli hiseq nextseq
workhors growth rate estim balanc illumina portfolio
miniseq miseq hiseq actual declin
illumina revenu contribut novaseq hiseq nextseq
follow new product updat industri confer start
one top question receiv sustain driver
consum growth compani elast demand one top debat
compani drive expand competit advantag drive
price sequenc also risk cannib compani revenu
lower price point believ price continu annual headwind illumina
innov drive price per gb sequenc launch hiseq
expand whole genom market significantli also greatli reduc
price sequenc give sens launch hiseq significantli
reduc price per gb sequenc hiseq famili platform
hiseq
expect similar step-down play sequenc transit hiseq
custom toward novaseq launch novaseq sequenc platform
custom focus whole-genom sequenc speed throughput advantag
rel legaci hiseq hiseq product line estim price per gb
sequenc novaseq current though anticip innov
ultim drive price lower time estim per gb
competitor confer highlight hiseq custom
adopt novaseq instal base stand custom
oper approxim hiseq instrument end compani
believ hiseq hiseq custom eventu transit novaseq
estim novaseq order custom either new
upgrad compani desktop sequenc platform
import continu monitor level adopt new custom
consum growth deceler past two year believ
import show inflect show elast out-weight
price reduct post consum growth
year prior recent year cost sequenc
decreas introduct hiseq recent novaseq
believ volum sequenc continu increas believ downward
pressur price sequenc serv headwind consum
growth model consum growth repres modest
improv ramp-up novaseq instal base well easi comp
posit higher expect sequenc pull-through could provid lever
increment volum growth model pull-through theoret
maximum around million per instrument per flow cell run everi day
novaseq certainli util workhors identifi custom
util level expect meaning lower said work
transit novaseq without correspond uptick demand elast
compani would cannib work lower price point model
consum growth slow
specif novaseq model pull-through per instrument expect
placement grow model uptick gb
sequenc year novaseq launch off-set price reduct
work transit hiseq novaseq
analysi consum growth price vs gb sequenc
provid addit commentari iseq launch expand
portfolio breadth lower-throughput end sequenc market view
instrument nice addit portfolio though addit growth
vs high-throughput platform compani describ iseq inexpens fast
easi use sequenc iseq util best-in-bre sequenc
synthesi sb chemistri coupl complementari metal-oxide-semiconductor
cmo detect technolog iseq target address market
potenti custom rang current owner new-to- custom iseq
gener million read greater per run run-tim rang
hour price per sampl rang addit
sequenc cost less instal custom less one hour
current take order iseq shipment expect begin
acceler follow manufactur scale
addit iseq launch announc partnership thermo fisher
allow compani commerci thermo fisher ion ampliseq
technolog research custom ceo franci desouza note break-out
session agreement stem mutual understand two
compani thermo fisher develop best-in-class amplicon technolog allow
effect captur dna rna small amount sampl thermo fisher
provid ion ampliseq technolog distribut directli
custom name ampliseq agreement preclud
thermo fisher sell ampliseq technolog current new sequenc
custom believ agreement commend show illumina
willing partner best class product even mean partner
major competitor thermo fisher give compani new revenu growth
access sizabl instal base
result ahead expect note execut
histor inconsist pre-announc earn miss
recent conserv set expect
pre-announce miss last quarter look back origin set
ep guidanc ultim beat estim actual result
see chart set guidanc ultim beat estim
actual result compani beat origin forecast
driven larg part greater adopt hiseq nextseq introduct
well robust growth compani end market custom final result
came higher initi expect compani deliv two
uncharacterist miss compani better job manag expect
start guidanc post actual non-gaap ep believ
inconsist execut exemplifi inher difficulti forecast
busi natur believ present risk result valuat
guidanc cadenc ep
continu wrestl right valuat recommend invest
compani clear market leader next-gener sequenc
fastest grow market life scienc tool technolog opinion matter
way diagnost market move genom expect play critic role
backbon innov addit compani invest thesi cater
well wide array investor base healthcar technolog even consum
audienc growth perspect look outsid life scienc tool
coverag find compani similar profil chart weve
analyz six large-cap internet name make interest set peer given size
growth trajectori interestingli trade doubl sale
multipl internet compar compani quadrupl multipl
look ev sale growth
thomson one consensu data compani
note price
note price
novaseq launch expect drive inflect sequenc instrument
revenu address dont believ address capac concern
market question whether compani abl expand market
someth done previou product launch addit
concern list variou risk thesi
secur fund custom
academ side busi beneficiari better nih
fund repres compani revenu posit
budget final increas nih budget clear
revenu y/i growth
presid trump sight set cut budget note
nih fund strong bipartisan support
clinic busi price code good first step
industri toward formal reimburs price code panel
gene two provid price recommend
pama rate remain larg unchang
posit reimburs today panel spars formal
reimburs rate continu move clinic busi forward
although lower level hope convers rate
continu make challeng low-volum site adopt technolog
common critiqu heard commun hospit includ
expertis manag equip keep capit cost
enough volum run technolog effici
new competit enter marketplac view new
market entrant direct threat believ potenti
earn busi histor would migrat toward driven
upsid expect specif whole-human genom sequenc oxford
nanopor continu execut toward earli access launch promethion
appli market pacbio announc sequel octob target sequenc
thermo fisher earn nice nich ion pgm tumor base sequenc
commerci generead workflow approach
releas revenu result
line compani
pre-announce januari report revenu million
higher prior estim million repres y/i growth
compani attribut beat strength sale compani
consum grew quarter driven increas util
high-throughput system novaseq well better-than-expect nextseq
perform includ sequenc consum quarter stock
order one novaseq custom said even exclud order novaseq
consum still would grown sequenti rel low base illumina
place around novaseq quarter compani note flow
cell catalyst demand quarter microarray strong quarter
driven continu demand consum genom market
revenu growth geographi
gener revenu consum driven
million sequenti step consum look back increas
instal base instrument market consum pull follow servic
revenu revenu grew y/i due mainten contract larger
instal base genotyp servic consum demand
mix revenu instrument vs recur
revenu increas y/i million acceler sequenti
third consecut quarter consum grew quarter though benefit
larg one-tim million stock order novaseq primari driver
consum growth quarter grow sequenti exclud stock
order nextseq util came guid rang
believ miseq pull fell within rang set
pull-through guidanc rang miniseq manag commentari
impli util fell within rang interestingli despit on-going novaseq
upgrad cycl hiseq hiseq consum increas sequenti quarter
instrument revenu improv y/i result demand novaseq high
shipment quarter expect hiseq hiseq shipment weaker
quarter servic revenu also strong quarter grow y/i
novaseq high throughput sequenc platform custom focus whole-
genom sequenc advantag rel legaci hiseq hiseq product
line instal base hiseq hiseq instrument compani
address larg market opportun base instrument sale alon asp
would repres billion instrument revenu opportun upsid
would driven market expans drive higher consum revenu
said placement cannib exist instrument consum opportun
would limit note consum cost per sampl like go
applic mean consum revenu could actual declin
per-box basi view launch make sens revolutionari
product aim drive replac cycl put rest concern
around revenu visibl near term long-term overcapac concern
like remain compani tri expand market beyond current instal
company/systemlaunchedinstru costrun costrun lengthrun speedthroughputpric per gbilluminaiseq fisher life ion day all-in n/an/abgi complet genomicsrevoloc ii long nanopor barclay illumina inc
design system larg market opportun mind note
system allow highest-throughput achiev lower sequenc cost
much lower capit commit rel hiseq hiseq
compani believ architectur novaseq platform eventu
allow achiev genom system use newli develop
flow cell allow higher-throughput increas speed-to-result
maintain accuraci earlier system compani launch novaseq
three flow cell option three flow cell throughout
capabl hiseq respect modestli
reduc speed-to-result hiseq day day novaseq
price capabl run three flow cell earn
announc cancel novaseq flow cell
custom primarili demand novaseq instrument
hiseq anticip demand hiseq weaker quarter custom
opt novaseq platform note ship hand
hiseq instrument quarter importantli focus convert exist
hiseq custom novaseq remind hiseq launch
per system januari announc launch hiseq
enhanc leverag capabl hiseq system
hiseq price reagent price per gb similarli
hiseq price provid half output lower reagent
costs/fast run time base commentari assum util
low end compani guid rang per instrument said
note hiseq consum revenu grew sequenti quarter hiseq
consum expect trend downward throughout
hiseq launch novaseq plan drive replac cycl
hiseq custom come year launch hiseq
sequenc whole human genom compani market product
 sell ten instrument increas throughput larg genom center
reach covet genom price system million
order come stronger expect interestingli despit novaseq
launch hiseq consum revenu grew sequenti quarter
expect signific replac cycl instrument follow
recent launch flow cell said compani note number
custom need finish current project upgrad compani
place hiseq instrument quarter
januari announc sell hiseq five system
configur known hiseq hiseq allow product center
adopt high-throughput whole genom sequenc lower capit invest
 full util set-up estim sequenc
genom year compani expect sell hiseq system million
addit hiseq xs million thereaft sequenc cost per gb
expect approxim versu hiseq
nextseq launch nextseq system fill nich product
portfolio hiseq miseq instrument product flex whole
human genom sequenc target panel price per system
estim compani place nextseq global pull-through
guid rang strength product
revenu growth
also launch nextseq combin microarray scan
nextseq sequenc system initi array qualifi system
cytogenet pgd applic expect enabl broad rang
applic reproduct health genet health oncolog adapt
allow lab gain access array sequenc singl capital-expenditure
miseq expect util miseq fell within compani guid rang
quarter sinc launch miniseq encourag lower
expect level miseq cannib ultim believ
market desktop instrument minimum estim place
though could make argument market size
product price unit expect annual
pull-through consum
miniseq launch januari miniseq compani smallest benchtop
sequenc design target sequenc applic smaller lab cost
instrument roughli believ pull number quarter
rang model current instal base instrument
array revenu increas y/i quarter million strength
driven primarili instrument servic consum growth
also solid quarter similarli demand driven strength
direct-to-consum market remind provid in-hous test servic
dtc test compani notabl ancestrydna
gross margin improv y/i driven posit mix strength sequenc
consum easier comp impact novaseq launch
compani non-gaap gross margin y/i q/q
gross margin expect slightli keep mind better margin
consum revenu grew y/i revenu outpac instrument growth
y/i line servic growth ebitda margin
y/i due flow gross margin line lower helix expens
partial off-set higher stock-bas compens expens
 declin y/i revenu ex-comp sg ex-comp
decreas y/i revenu despit top-lin leverag adjust oper
expens million flat sequenti
non-gaap sg revenu
non-gaap ep increas y/i expect tax reform
add ep adj tax rate improv compani
leverag strong top line perform y/i margin improv deliv solid
earn growth excess tax benefit stock-bas comp contribut ep
quarter
marginadj revenu dsg barclay illumina inc
quarterli non-gaap ep y/i growth
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
